Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid Leukemia in accelerated phase

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 2, 2014, Pages

  Ohanian, Maro ^a   Kantarjian, Hagop M ^a   Quintas Cardama, Alfonso ^a   Jabbour, Elias ^a   Abruzzo, Lynne ^a   Verstovsek, Srdan ^a   Borthakur, Gautam ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Champlin, Richard ^a   Pierce, Sherry ^a   Alattar, Mona Lisa ^a   Trinh, Long Xuan ^a   Luthra, Raja ^a   Ferrajoli, Alessandra ^a   Kadia, Tapan ^a   O'brien, Susan ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Accelerated phase CML (CML AP); Complete cytogenetic response (CCyR); Major molecular response (MMR); Second generation TKI (2GTKIs); Tyrosine kinase inhibitors (TKI)

Indexed keywords

ABELSON KINASE; DASATINIB; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; GENETICS; LEUKEMIA, MYELOID, ACCELERATED PHASE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896405273     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.08.008     Document Type: Article

References (30)

1. H. Kantarjian, M. Talpaz, and S. O'Brien et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience Cancer 103 2005 2099 2108.
2. B.J. Druker, C.L. Sawyers, and H. Kantarjian et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042.
3. J. Cortes Natural history and staging of chronic myelogenous leukemia Hematol Oncol Clin North Am 18 2004 569 584 viii.
4. H.M. Kantarjian, D. Dixon, and M.J. Keating et al. Characteristics of accelerated disease in chronic myelogenous leukemia Cancer 61 1988 1441 1446.
5. J. Cortes, and H. Kantarjian Advanced-phase chronic myeloid leukemia Semin Hematol 40 2003 79 86.
6. H. Kantarjian, S. O'Brien, and E. Jabbour et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience Blood 119 2012 1981 1987.
7. M. Brave, V. Goodman, and E. Kaminskas et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate Clin Cancer Res 14 2008 352 359.
8. A. Hochhaus, F. Giles, and J. Apperley et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study Haematologica 94 suppl 2 2009 256 (abstract 0631).
9. F. Palandri, F. Castagnetti, and G. Alimena et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up Haematologica 94 2009 205 212.
10. T. Lahaye, B. Riehm, and U. Berger et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 2005 1659 1669.
11. J.E. Cortes, M. Talpaz, and F. Giles et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy Blood 101 2003 3794 3800.
12. H.M. Kantarjian, S. O'Brien, and J.E. Cortes et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate Clin Cancer Res 8 2002 2167 2176.
13. T. Hughes, M. Deininger, and A. Hochhaus et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37.
14. Public summary of positive opinion for orphan designation of imatinib mesilate for treatment of chronic myeloid leukaemia. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2009/10/ WC500006437.pdf. Accessed: January 17, 2013.
15. Highlights of prescribing information. Available at: http://www.pharma. us.novartis.com/product/pi/pdf/gleevec-tabs.pdf. Accessed: january 17, 2013.
16. J.R. Johnson, J.R. Bross, and M. Cohen et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Clin Cancer Res 9 2003 1972 1979.
17. F. Palandri, I. Iacobucci, and F. Castagnetti et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome Haematologica 93 2008 770 774.
18. S.G. O'Brien, F. Guilhot, and R.A. Larson et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004.
19. M. Deininger, S. O'Brien, and F. Guilhot et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib Blood 114 2009 462 (abstract 1126).
20. J. Apperley, J. Cortes, and D. Kim Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial J Clin Oncol 27 2009 3472 3479.
21. D. Rea, G. Etienne, and F. Nicolini et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia Leukemia 26 2012 2254 2259.
22. M. Talpaz, R.T. Silver, and B.J. Druker et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937.
23. P.D. le Coutre, F.J. Giles, and A. Hochhaus et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results Leukemia 26 2012 1189 1194.
24. National Marrow Donor Program. Chronic Myelogenous Leukemia (CML) Outcomes. Available at: http://marrow.org/Physicians/Unrelated-Search-and- Transplant/NMDP-Outcomes/CML-Outcomes/Chronic-Myelogenous-Leukemia-(CML) -Outcomes.aspx-ref1. Accessed: december 22, 2012.
25. A. Gratwohl, R. Brand, and J. Apperley et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Haematologica 91 2006 513 521.
26. Q. Jiang, L.P. Xu, and D.H. Liu et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase Blood 117 2011 3032 3040.
27. P. Jain, H. Kantarjian, and A. Nazha et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities Blood 121 2013 4867 4874.
28. M.E. O'Dwyer, M.J. Mauro, and G. Kurilik et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML Blood 100 2002 1628 1633.
29. H.M. Kantarjian, M.J. Keating, and E.H. Estey et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine J Clin Oncol 10 1992 772 778.
30. J. Cortes, and M.E. O'Dwyer Clonal evolution in chronic myelogenous leukemia Hematol Oncol Clini North Am 18 2004 671 684 x.